FDA Chief Counsel Says Generic Firms Make Strong Case For Preemption
This article was originally published in The Pink Sheet Daily
Executive Summary
Generic product liability suits are on the rise, which could result in more generic drug makers arguing for federal preemption, Bradshaw says.
You may also be interested in...
Final Rx Labeling Rule Should Not Preempt State Product Liability Laws, States Say
National Conference of State Legislatures alleges that FDA’s final labeling rule will include language limiting state product liability laws.
Final Rx Labeling Rule Should Not Preempt State Product Liability Laws, States Say
National Conference of State Legislatures alleges that FDA’s final labeling rule will include language limiting state product liability laws.
FDA Chief Counsel Is Assistant Attorney General Bradshaw
Bradshaw brings extensive high-level government service experience to the position as he permanently replaces former Chief Counsel Troy. Deputy Chief Counsel Masoudi has served in the position on an interim basis since Troy’s departure in November.